# Bariatric Surgery vs. Semaglutide vs. Tirzepatide

> **NCT06803888** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Ali Aminian** · enrollment: 125 (estimated)

## Conditions studied

- Obesity and Obesity-related Medical Conditions

## Interventions

- **PROCEDURE:** Bariatric Surgery
- **DRUG:** Semaglutide
- **DRUG:** Tirzepatide

## Key facts

- **NCT ID:** NCT06803888
- **Lead sponsor:** Ali Aminian
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-01-29
- **Primary completion:** 2027-07-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 125 (ESTIMATED)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06803888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06803888, "Bariatric Surgery vs. Semaglutide vs. Tirzepatide". Retrieved via AI Analytics 2026-09-06 from https://api.ai-analytics.org/clinical/NCT06803888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*